Alice Epitropoulos, MD
Ophthalmology · Columbus, OHNPI 1205812997
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 30.8% of the total. Among ophthalmology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 802 payments — averaging $662.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$164K
- AbbVie$72K
- Ocular Therapeutix, Inc.$40K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$39K
- Alcon$35K
- Sun Pharmaceutical Industries Inc.$30K
- plus $152K from 33 others
Across 56 payments — averaging $3228.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$85K
- Sun Pharmaceutical Industries Inc.$59K
- Bausch & Lomb Americas Inc.$19K
- Dompe US, Inc.$10K
- Oyster Point Pharma, Inc.$3K
- Johnson & Johnson Surgical Vision, Inc.$2K
- plus $2K from 3 others
What the payments were for
- Consulting fees$215,67641%
- Speaking & faculty fees$252,84948%
- Travel & lodging$28,7475%
- Food & beverage$23,4354%
- Education$3870%
- Gifts$8,2812%
- Other$2,1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$71,704
- XIIDRA$59,584
- DEXTENZA$39,177
- VUITY$34,222
- enVista MX60 IOL$33,778
- TRYPTYR$33,441
- CEQUA$27,849
- ENVISTA ENVY IOL$23,198
- LOTEMAX SM$15,189
- IC-8 Apthera IOL$14,903
- STELLARIS ELITE$14,903
- TYRVAYA$13,332
- RESTASIS MULTIDOSE$12,215
- Oxervate$10,733
- ATLAS 9000$10,341
- INVELTYS$10,198
- Ryzumvi$9,900
- Crystalens Accommodating IOL (AT-52AO)$9,486
- Flarex$8,162
- ILUX$7,410
How this compares
$531,489 in reported general payments places this provider in the 95th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 25 | $1,290,414 |
| RestasisCyclosporine | 208 | $196,974 |
| MieboPerfluorohexyloctane/Pf | 118 | $106,675 |
| VevyeCyclosporine | 55 | $49,607 |
| XdemvyLotilaner | 26 | $48,414 |
| XiidraLifitegrast | 32 | $41,821 |
| CequaCyclosporine | 33 | $26,909 |
| TyrvayaVarenicline Tartrate | 38 | $22,046 |
| Cyclosporine | 61 | $21,239 |
| Lotemax SmLoteprednol Etabonate | 67 | $16,686 |
| ProlensaBromfenac Sodium | 46 | $16,024 |
| Prednisolone Acetate | 153 | $4,447 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $4,369 |
| MoxifloxacinMoxifloxacin Hcl | 230 | $4,291 |
| Bepotastine Besilate | 29 | $2,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $23,789 | $1,290,41425 claims |
| AbbVieRestasis | $72,232 | $196,974208 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $163,533 | $148,497150 claims |
| Harrow Eye, LLCVevye | $1,932 | $49,60755 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $3,047 | $48,41426 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa | $39,076 | $32,710113 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $30,486 | $26,90933 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $23,782 | $22,04638 claims |
| AlconSimbrinza | $34,554 | $4,36922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Columbus
- Steven KatzColumbus$256K
- David LehmannColumbus$58K
- Lisa BorkowskiColumbus$25K
- Thomas MendelColumbus$15K
- Norman BakerColumbus$11K
- Carrie LembachColumbus$11K
- John ChristoforidisColumbus$10K
- Peter KaiserCleveland$1.5M
- Gregory EippertMentor$813K
- Robert OsherCincinnati$720K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.